BMCL Digest
Recent progress in sodium channel modulators for pain

https://doi.org/10.1016/j.bmcl.2014.06.038Get rights and content
Under a Creative Commons license
open access

Abstract

Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery.

Keywords

Voltage-gated sodium channels
Electrophysiology screening
Sodium channel toxins
Sodium channel structure
Sodium channel drugs

Cited by (0)